2019
Longitudinal Findings from a Randomized Clinical Trial of Varenicline for Alcohol Use Disorder with Comorbid Cigarette Smoking
Bold KW, Zweben A, Fucito LM, Piepmeier ME, Muvvala S, Wu R, Gueorguieva R, O'Malley SS. Longitudinal Findings from a Randomized Clinical Trial of Varenicline for Alcohol Use Disorder with Comorbid Cigarette Smoking. Alcohol Clinical And Experimental Research 2019, 43: 937-944. PMID: 30817018, PMCID: PMC7039307, DOI: 10.1111/acer.13994.Peer-Reviewed Original ResearchConceptsEnd of treatmentAlcohol use disorderHeavy drinking daysMedical managementCigarette smokingComorbid cigarette smokingUse disordersDrinking daysCo-occurring alcohol use disorderHigh ratePlacebo-controlled trialBetter clinical outcomesAssessment of alcoholPercent of participantsVarenicline treatmentClinical outcomesSmoking abstinenceParallel groupClinical trialsTimeline FollowVareniclineSmoking behaviorAlcohol treatmentPosttreatment outcomesMultisite trialImpact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant
Wilkinson ST, Farmer C, Ballard E, Mathew SJ, Grunebaum MF, Murrough JW, Sos P, Wang G, Gueorguieva R, Zarate CA. Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant. Neuropsychopharmacology 2019, 44: 1233-1238. PMID: 30653192, PMCID: PMC6785710, DOI: 10.1038/s41386-019-0317-8.Peer-Reviewed Original ResearchConceptsTrial of ketamineEffectiveness of midazolamRapid acting antidepressantsSaline-controlled studyPatient-level analysisEffects of ketamineImpact of midazolamClinical outcomesMidazolam dosesKetamine dosesKetamine studiesMood disordersMidazolamResponse rateModel-estimated rateKetamineTrial outcomesSalineEffect size estimatesGreater improvementEffect sizeDosesControl conditionOutcomesSimilar results
2016
Imaging mass spectrometry assists in the classification of diagnostically challenging atypical Spitzoid neoplasms
Lazova R, Seeley EH, Kutzner H, Scolyer RA, Scott G, Cerroni L, Fried I, Kozovska ME, Rosenberg AS, Prieto VG, Shehata BM, Durham MM, Henry G, Rodriguez-Peralto JL, Riveiro-Falkenbach E, Schaefer JT, Danialan R, Fraitag S, Vollenweider-Roten S, Sepehr A, Sangueza M, Hijazi N, Corredoira Y, Kowal R, Harris OM, Bravo F, Boyd AS, Gueorguieva R, Caprioli RM. Imaging mass spectrometry assists in the classification of diagnostically challenging atypical Spitzoid neoplasms. Journal Of The American Academy Of Dermatology 2016, 75: 1176-1186.e4. PMID: 27502312, PMCID: PMC5112112, DOI: 10.1016/j.jaad.2016.07.007.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge FactorsAgedAged, 80 and overChildChild, PreschoolDiagnosis, DifferentialFemaleHumansLymphatic MetastasisMaleMass SpectrometryMelanomaMiddle AgedNeoplasm Recurrence, LocalNevus, Epithelioid and Spindle CellProteinsRetrospective StudiesRisk AssessmentSentinel Lymph Node BiopsySkin NeoplasmsTreatment OutcomeTumor BurdenYoung AdultConceptsAtypical spitzoid neoplasmsClinical group 1Clinical behaviorSpitzoid melanomaHistopathological diagnosisGroup 1Spitzoid neoplasmsClinical group 2Greater tumor thicknessRetrospective collaborative studyAggressive clinical behaviorClinical outcomesRisk stratificationTumor thicknessPoor outcomeWorse clinical behaviorGroup 2Older ageClinical groupsDiagnosisSpitz neviMelanomaStrong associationProteomic signaturePatients
2015
Predictors of Abstinence From Heavy Drinking During Follow-Up in COMBINE.
Gueorguieva R, Wu R, Fucito LM, O'Malley SS. Predictors of Abstinence From Heavy Drinking During Follow-Up in COMBINE. Journal Of Studies On Alcohol And Drugs 2015, 76: 935-41. PMID: 26562602, PMCID: PMC4712662, DOI: 10.15288/jsad.2015.76.935.Peer-Reviewed Original ResearchConceptsLong-term outcomesBetter long-term outcomesBetter clinical outcomesDrinking outcomesHeavy drinking daysLogistic regression analysisStrongest predictorLogistic regression modelsPredictors of abstinenceFair classification accuracyPatient characteristicsClinical outcomesTerm outcomesCombined PharmacotherapiesClinical trialsBaseline predictorsTreatment outcomesTreatment phaseOptimizing outcomesDrinking daysBetter outcomesAlcohol Dependence (COMBINE) StudyBehavioral interventionsHeavy drinkingAlternative interventionsPredicting Meaningful Outcomes to Medication and Self-Help Treatments for Binge-Eating Disorder in Primary Care: The Significance of Early Rapid Response
Grilo CM, White MA, Masheb RM, Gueorguieva R. Predicting Meaningful Outcomes to Medication and Self-Help Treatments for Binge-Eating Disorder in Primary Care: The Significance of Early Rapid Response. Journal Of Consulting And Clinical Psychology 2015, 83: 387-394. PMID: 25622201, PMCID: PMC4380674, DOI: 10.1037/a0038635.Peer-Reviewed Original ResearchConceptsBinge-eating disorderSelf-help cognitive behavioral therapyPrimary care settingObese patientsFourth treatment weekBaseline clinical characteristicsBetter clinical outcomesPrimary care physiciansObese patient groupRandomized clinical trialsStrong prognostic indicatorSelf-help interventionEating-disorder psychopathologyImportant clinical implicationsCognitive behavioral therapyAntiobesity medicationsClinical characteristicsMixed-effects model analysisClinical outcomesPercent weight lossPatient groupPrognostic indicatorTreatment weekClinical trialsResearch clinicians
2014
Treatment of binge eating disorder in racially and ethnically diverse obese patients in primary care: Randomized placebo-controlled clinical trial of self-help and medication
Grilo CM, Masheb RM, White MA, Gueorguieva R, Barnes RD, Walsh BT, McKenzie KC, Genao I, Garcia R. Treatment of binge eating disorder in racially and ethnically diverse obese patients in primary care: Randomized placebo-controlled clinical trial of self-help and medication. Behaviour Research And Therapy 2014, 58: 1-9. PMID: 24857821, PMCID: PMC4074556, DOI: 10.1016/j.brat.2014.04.002.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAnti-Obesity AgentsBinge-Eating DisorderBlack or African AmericanBody WeightCognitive Behavioral TherapyCombined Modality TherapyCyclobutanesDouble-Blind MethodFemaleHispanic or LatinoHumansMaleMiddle AgedObesityPrimary Health CareSelf CareTime FactorsTreatment OutcomeWhite PeopleYoung AdultConceptsSelf-help cognitive behavioral therapyDiverse obese patientsAnti-obesity medicationsObese patientsModerate clinical outcomePercent weight lossTime interaction effectsWeight lossClinical outcomesPrimary careRandomized placebo-controlled clinical trialSecond placebo-controlled trialPlacebo-controlled clinical trialAcute weight lossPlacebo-controlled trialDouble-blind fashionDiscontinuation of medicationPrimary care settingWeight loss maintenanceSpecialist treatment centresTreatment of bingeDiverse patient groupsSelf-help CBTBinge-eating frequencyDemographic factors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply